Therapy with oncolytic viruses: progress and challenges

Oncolytic viruses (OVs) are an emerging class of cancer therapeutics that offer the benefits of selective replication in tumour cells, delivery of multiple eukaryotic transgene payloads, induction of immunogenic cell death and promotion of antitumour immunity, and a tolerable safety profile that lar...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Clinical oncology 2023-03, Vol.20 (3), p.160-177
Main Authors: Shalhout, Sophia Z, Miller, David M, Emerick, Kevin S, Kaufman, Howard L
Format: Article
Language:English
Subjects:
Cancer
Cell death
Clinical trials
Humans
Immunogenicity
Immunotherapy
Melanoma
Oncolysis
Oncolytic Virotherapy - adverse effects
Oncolytic Viruses
Patients
Skin Neoplasms - pathology
Skin Neoplasms - therapy
Toxicity
Tumors
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oncolytic viruses (OVs) are an emerging class of cancer therapeutics that offer the benefits of selective replication in tumour cells, delivery of multiple eukaryotic transgene payloads, induction of immunogenic cell death and promotion of antitumour immunity, and a tolerable safety profile that largely does not overlap with that of other cancer therapeutics. To date, four OVs and one non-oncolytic virus have been approved for the treatment of cancer globally although talimogene laherparepvec (T-VEC) remains the only widely approved therapy. T-VEC is indicated for the treatment of patients with recurrent melanoma after initial surgery and was initially approved in 2015. An expanding body of data on the clinical experience of patients receiving T-VEC is now becoming available as are data from clinical trials of various other OVs in a range of other cancers. Despite increasing research interest, a better understanding of the underlying biology and pharmacology of OVs is needed to enable the full therapeutic potential of these agents in patients with cancer. In this Review, we summarize the available data and provide guidance on optimizing the use of OVs in clinical practice, with a focus on the clinical experience with T-VEC. We describe data on selected novel OVs that are currently in clinical development, either as monotherapies or as part of combination regimens. We also discuss some of the preclinical, clinical and regulatory hurdles that have thus far limited the development of OVs.
ISSN:1759-4774
1759-4782
DOI:10.1038/s41571-022-00719-w